Bladder cancer nursing: assessment, treatment, and NCLEX review

Bladder cancer ranks among the most common urologic malignancies in the United States, with roughly 83,000 new cases diagnosed annually. The disease disproportionately affects older men — the median age at diagnosis is 73 — and carries a high recurrence rate that makes lifelong surveillance a clinical reality for most patients. Nursing students encounter bladder cancer on NCLEX through two high-yield scenarios: the management of intravesical BCG therapy (with its specific safety protocols around live bacteria), and the post-operative care of urinary diversions following radical cystectomy. This reference covers both, alongside the pathophysiology, staging, diagnostics, and treatment landscape needed to understand the clinical picture from presentation through follow-up.

Pathophysiology and histologic classification

The urothelium — the transitional epithelium lining the bladder, ureters, and renal pelvis — is the site of origin for the vast majority of bladder tumors. Urothelial carcinoma (also called transitional cell carcinoma, or TCC) accounts for approximately 90% of all bladder cancers in the United States. The remaining 10% are divided between squamous cell carcinoma (SCC, ~5%) and adenocarcinoma (~2%), with rare neuroendocrine and mixed histologies making up the rest.

The biologic distinction between histologic types matters clinically. Urothelial carcinoma arises from chronic mucosal irritation by carcinogens excreted in urine — the bladder serves as a reservoir, meaning the mucosa sits in prolonged contact with metabolized toxins. Squamous cell carcinoma carries a different epidemiologic fingerprint: it is associated with chronic parasitic infection (specifically Schistosoma haematobium, endemic in sub-Saharan Africa and the Middle East), long-standing urinary catheters, and recurrent bacterial infection. Adenocarcinoma is uncommon and typically arises from the urachal remnant or in patients with bladder exstrophy.

Superficial vs. muscle-invasive disease

The most clinically meaningful distinction in bladder cancer is whether the tumor has invaded the muscularis propria (detrusor muscle). This binary division — non-muscle-invasive (NMIBC) versus muscle-invasive (MIBC) — drives the entire treatment algorithm.

Non-muscle-invasive bladder cancer (approximately 75% of newly diagnosed cases) is confined to the urothelium or lamina propria. While it is treatable with organ-preserving surgery, it carries a recurrence rate of 60–70% and a 10–30% risk of progression to muscle-invasive disease, which is why close surveillance is mandated even after complete resection.

Muscle-invasive bladder cancer has breached the detrusor muscle. Left untreated, MIBC carries a median survival under two years. Standard care involves radical cystectomy (removal of the bladder) with urinary diversion — a major operation with profound nursing implications.

Metastatic disease involves regional lymph nodes (N1–N3) or distant organs (lungs, liver, bone, peritoneum) and requires systemic therapy.

AJCC/TNM staging and nursing implications

Risk factors

Understanding bladder cancer risk factors is high-yield for NCLEX and for patient education during primary prevention counseling.

Tobacco smoking is the single largest modifiable risk factor, accounting for approximately 50% of all cases. Both current and former smokers carry elevated risk; risk declines after cessation but remains elevated for decades. Every bladder cancer patient should receive tobacco cessation counseling regardless of current smoking status.

Occupational exposures represent the second largest category. Workers historically exposed to aromatic amines — including aniline dyes, benzidine, and beta-naphthylamine — carry significantly elevated lifetime risk. Affected industries include rubber manufacturing, textile dyeing, leather tanning, hairdressing, and aluminum smelting. The latency period between exposure and diagnosis can be 20–50 years.

Chronic bladder irritation from specific causes predisposes to distinct histologic subtypes. Schistosoma haematobium infection (common in endemic regions of Africa and the Middle East) causes chronic mucosal inflammation and is the leading cause of squamous cell carcinoma worldwide. Chronic indwelling urinary catheters and recurrent urinary tract infections (particularly those with urease-producing organisms causing struvite stone formation) also carry elevated SCC risk. See the UTI nursing reference for clinical detail on urinary infections.

Cyclophosphamide, an alkylating chemotherapy agent, produces the metabolite acrolein, which accumulates in urine and directly irritates the urothelium. Patients who have received cyclophosphamide for prior malignancies or rheumatologic conditions carry a 4–9-fold elevated risk of urothelial carcinoma. Concurrent mesna (2-mercaptoethane sulfonate) is administered with high-dose cyclophosphamide to bind acrolein in the urine and reduce bladder toxicity.

Demographic factors: male sex (male-to-female incidence ratio approximately 3–4:1), White race, and age older than 55 years are established risk factors. The elevated male risk is partly explained by occupational exposure patterns and higher historical smoking rates, though hormonal differences may also play a role.

Clinical presentation

Hematuria — the cardinal symptom

Painless gross hematuria is the most common presenting symptom of bladder cancer, occurring in 80–90% of patients. The absence of pain is the clinically important detail — it distinguishes bladder cancer from hematuria caused by nephrolithiasis (which is painful) or urinary tract infection (which is accompanied by irritative symptoms). In any patient older than 40–50 presenting with painless hematuria, bladder malignancy must be excluded before attributing the symptom to a benign etiology.

Microscopic hematuria (RBCs detected on urinalysis without visible discoloration) is also associated with bladder cancer, though it is less specific. Intermittent hematuria — episodes of bloody urine separated by periods of apparent normalcy — is characteristic of bladder cancer and should not be falsely reassuring.

Irritative voiding symptoms

Carcinoma in situ (CIS/Tis) and high-grade NMIBC classically present with irritative voiding symptoms: frequency, urgency, and dysuria. These symptoms are indistinguishable from a urinary tract infection or pyelonephritis, and bladder cancer is frequently misdiagnosed as recurrent UTI in older adults, delaying diagnosis. The clinical rule: hematuria plus irritative voiding symptoms in an older patient is bladder cancer until proven otherwise.

Advanced and metastatic disease

Locally advanced disease may produce flank or pelvic pain from ureteral obstruction, a palpable pelvic mass, lower extremity edema from lymphatic or venous obstruction, or rectal pressure from posterior extension. Bone metastases cause focal bone pain and carry a risk of pathologic fracture. Constitutional symptoms — weight loss, fatigue, anorexia — suggest systemic disease and advanced staging.

Diagnostic workup

Urinalysis and urine cytology

Urinalysis will typically reveal hematuria (gross or microscopic). Urine cytology — microscopic examination of exfoliated cells in voided or catheterized urine — is a useful adjunct for detecting high-grade disease. Cytology has high specificity (low false-positive rate) but poor sensitivity for low-grade tumors; a negative cytology does not exclude bladder cancer.

Cystoscopy with biopsy — gold standard

Cystoscopy is the gold standard for bladder cancer diagnosis. A flexible or rigid endoscope is passed into the bladder via the urethra, allowing direct visualization of the urothelium. Any visible lesion undergoes biopsy. Cystoscopy cannot be replaced by imaging or cytology alone for definitive diagnosis.

Nursing preparation for cystoscopy includes informed consent, patient education that the procedure involves a scope passed through the urethra, and explaining that some post-procedure hematuria and dysuria are expected and typically resolve within 24–48 hours.

CT urography

CT urography provides cross-sectional imaging of the kidneys, ureters, and bladder with contrast enhancement during the excretory phase. It is used to evaluate the upper urinary tract (which cannot be seen on cystoscopy), assess tumor extent, and screen for synchronous upper tract urothelial carcinoma, which occurs in 2–4% of patients. See the AKI nursing reference for contrast nephropathy prevention and the CKD nursing reference for implications in patients with renal impairment.

TURBT — diagnostic and therapeutic

Transurethral resection of bladder tumor (TURBT) is performed under anesthesia. The cystoscope is advanced into the bladder, and a resectoscope loop removes all visible tumor. TURBT is simultaneously:

• Diagnostic: the resected specimen provides tissue for histologic staging (depth of invasion) and grade
• Therapeutic: for NMIBC, TURBT may constitute definitive surgical treatment

Adequate depth of resection to include muscularis propria is essential for accurate staging; superficial biopsies that miss muscle may understage T2 disease as T1, leading to undertreated muscle-invasive cancer. Post-TURBT hematuria is expected; patients are typically managed with continuous bladder irrigation (CBI) until urine clears.

Treatment by stage

Non-muscle-invasive disease (Ta, T1, Tis)

Initial treatment is TURBT. For patients at intermediate or high risk of recurrence or progression, adjuvant intravesical therapy is instilled directly into the bladder via urethral catheter after resection.

Intravesical BCG (Bacillus Calmette-Guérin) is the preferred adjuvant therapy for high-risk NMIBC, particularly CIS and high-grade T1 disease. BCG is a live attenuated strain of Mycobacterium bovis that induces a local immune response in the bladder mucosa, reducing recurrence and lowering progression risk. The specific nursing protocols for BCG are detailed in the next section.

Intravesical chemotherapy (most commonly mitomycin C) is used for low- to intermediate-risk disease or as an alternative when BCG is contraindicated or unavailable. A single instillation of mitomycin C immediately after TURBT (within 6 hours) has been shown to reduce early recurrence by flushing and destroying any circulating tumor cells dislodged during resection. Mitomycin C is an alkylating agent; nurses handling it should use appropriate chemotherapy precautions (gloves, gown). Patient-side precautions for mitomycin C are less stringent than for BCG — standard toilet flushing is adequate.

Muscle-invasive disease (T2 and above)

Radical cystectomy is the surgical gold standard for MIBC. In men, standard surgery removes the bladder, prostate, seminal vesicles, and pelvic lymph nodes (radical cystoprostatectomy). In women, the bladder, urethra, uterus, ovaries, and anterior vaginal wall are removed (anterior pelvic exenteration). Urinary diversion is required in all cases.

Neoadjuvant cisplatin-based chemotherapy (typically gemcitabine/cisplatin) administered before cystectomy improves 5-year overall survival by approximately 5–8% and is the standard of care for cisplatin-eligible patients with T2–T4 disease.

Bladder-preservation chemoradiation (concurrent cisplatin-based chemotherapy with external beam radiation) is an alternative for patients who decline cystectomy or are medically inoperable. Outcomes approach those of cystectomy in carefully selected patients. Nursing monitoring during chemoradiation includes radiation cystitis (hematuria, frequency, urgency), radiation proctitis (diarrhea, rectal bleeding), and cisplatin toxicity (nephrotoxicity, ototoxicity, myelosuppression, nausea).

Metastatic disease

Cisplatin-based combination chemotherapy is the standard first-line systemic treatment for metastatic urothelial carcinoma in cisplatin-eligible patients. Two regimens have comparable efficacy:

• MVAC (methotrexate, vinblastine, doxorubicin, cisplatin) — older regimen; significant toxicity (mucositis, myelosuppression, alopecia)
• Gemcitabine/cisplatin (GC) — preferred first-line option with similar efficacy and more favorable toxicity profile

Patients ineligible for cisplatin (impaired renal function, poor performance status, peripheral neuropathy, hearing loss) may receive carboplatin-based regimens.

Immune checkpoint inhibitors targeting the PD-1/PD-L1 axis have become standard second-line therapy and are emerging in first-line settings:

• Pembrolizumab (anti-PD-1) — approved for platinum-refractory metastatic urothelial carcinoma and for BCG-unresponsive high-risk NMIBC
• Atezolizumab (anti-PD-L1) — approved in platinum-ineligible patients

Nursing care for patients receiving checkpoint inhibitors centers on recognition and management of immune-related adverse events (irAEs). See the oncology nursing reference for irAE monitoring and management principles.

Chemotherapy and immunotherapy agents — key nursing considerations

BCG intravesical therapy — nursing priorities

BCG therapy deserves its own section because it involves unique safety considerations that frequently appear on NCLEX. BCG is a live attenuated strain of Mycobacterium bovis, the organism responsible for bovine tuberculosis. The live bacterial nature of the preparation creates specific handling, administration, and patient education requirements that distinguish BCG from conventional intravesical chemotherapy.

Indications and contraindications

BCG is indicated for high-risk NMIBC: CIS, high-grade T1, and Ta with high-risk features (multiple tumors, large tumor, rapid recurrence). It reduces the 5-year recurrence rate from approximately 70% to 30–40% and significantly reduces progression risk.

Contraindications to BCG instillation:

• Active urinary tract infection (BCG cannot be administered if urine is infected — risk of systemic BCG dissemination)
• Gross hematuria or traumatic catheterization at time of instillation (mucosal breach allows systemic absorption of live bacteria)
• Immunocompromised state (congenital or acquired; active immunosuppressant therapy)
• Active tuberculosis

Administration and retention protocol

BCG is reconstituted immediately before use and instilled into the bladder via urethral catheter. The patient must retain the BCG in the bladder for 2 hours — this prolonged dwell time is necessary for the immune response to develop. Patients are instructed to change position (lying on back, sides, prone) every 15–30 minutes during retention to ensure mucosal contact throughout the entire bladder.

After 2 hours, the patient voids in a sitting position. BCG is excreted alive in the voided urine.

Post-instillation hygiene (NCLEX high-yield)

Because BCG is a live mycobacterium, disinfection of the toilet is required for 6 hours after each void. Patients are instructed to pour undiluted household bleach (5.25% sodium hypochlorite) into the toilet and allow 15–20 minutes of contact before flushing. This protocol applies for the first 6 hours after each BCG treatment — a period corresponding to 3–4 voiding episodes. Male patients must void sitting down to minimize splash.

This detail is consistently tested on NCLEX: bleach disinfection × 6 hours after voiding, not just after the first void.

BCG therapy nursing checklist

Radical cystectomy and urinary diversion

When the bladder is surgically removed, urine must be diverted from the ureters to an alternative reservoir or outlet. Three main diversion types are used, each with distinct patient care requirements that are heavily tested on NCLEX and in clinical rotations.

Urinary diversion comparison

Ileal conduit stoma care — nursing priorities

The ileal conduit is the most commonly performed urinary diversion and the one most frequently assessed on NCLEX. Key nursing points:

Stoma assessment. A healthy stoma is beefy red, moist, and slightly edematous in the immediate post-operative period. Edema peaks in the first 24–72 hours then resolves. A dark, dusky, or black stoma indicates ischemia and requires immediate surgical evaluation. Stoma color assessment is the single most critical assessment at each nursing encounter.

Urostomy output. Urine will be the primary output. The presence of mucus in urostomy drainage is expected and normal — the ileal segment retains its mucus-secreting capacity after isolation. Patients should be educated that mucus does not indicate infection or wound breakdown. Blood in the urostomy output in the immediate post-operative period may be normal (small amounts from anastomotic sites and resection margins); frank hematuria or large clots should be reported.

Ureteral stents. In the immediate post-operative period, small tubes (ureteral stents) may be visible emerging from the stoma — typically two fine catheters, one per ureter. These are expected, temporary, and placed intraoperatively to protect the ureteral anastomoses while healing occurs. They are not signs of a complication. They are typically removed at the first post-operative clinic visit.

Peristomal skin. Urine is more alkaline and less corrosive than ileostomy output, but prolonged contact with the peristomal skin causes maceration and dermatitis. A properly fitting skin barrier and pouch system that creates a seal at the stoma base is essential. The barrier wafer should be cut to fit within 1/8 inch of the stoma edge.

Pouching system and output volume. The urostomy pouch should be emptied when one-third to one-half full to prevent the weight of urine from breaking the skin barrier seal. At night, the pouch is connected to a larger-volume leg or bedside drainage bag to allow uninterrupted sleep. Minimum acceptable urine output is 30 mL/hr (same standard as for any urologic post-operative patient).

Neobladder patients — specific education

Patients with orthotopic neobladders require thorough education before discharge. The neobladder lacks the neurologic connections of the native bladder — there is no sensation of normal bladder filling, and voiding does not occur reflexively. Patients must:

• Void on a timed schedule every 3–4 hours rather than waiting for urgency (which they will not feel normally, especially initially)
• Use Valsalva maneuver (bearing down abdominally) or Credé maneuver (manual suprapubic pressure) to initiate and maintain urine flow
• Learn intermittent self-catheterization for situations of incomplete emptying (a significant risk, particularly in women with orthotopic neobladder)
• Understand that nocturnal incontinence is common in the first 6–12 months — the neobladder does not contract reflexively during sleep; timed nocturnal voiding (setting an alarm) is often necessary

Mucus retention is a neobladder-specific complication. The ileal segment secretes mucus into the reservoir; if this mucus is not regularly expelled by voiding and catheterization, it can plug the urethra or reservoir outlet, causing acute urinary retention. Patients should increase fluid intake and consider periodic reservoir irrigation per urology protocol.

Post-radical cystectomy nursing priorities

The cystectomy patient is a major surgical patient. Standard post-operative assessments apply, with specific urologic monitoring layered on top.

Fluid and electrolyte monitoring. Ileal conduit and neobladder construction use bowel segments. The ileum absorbs chloride in exchange for bicarbonate when in contact with urine — in patients with ileal diversions, this can lead to hyperchloremic metabolic acidosis over time. Nursing should monitor serum bicarbonate and chloride in the post-operative period and during long-term follow-up. Patients with impaired renal function (reduced ability to compensate) are at highest risk. See the CKD nursing reference for acid-base monitoring principles. The AKI nursing reference covers post-operative acute kidney injury risk — a major concern in cystectomy patients given the surgical complexity and fluid shifts involved.

Urine output monitoring. Monitor bilateral ureteral stent outputs (often tracked separately in the immediate post-operative period) and total diversion output. Minimum output: 30 mL/hr. Falling output may indicate ureteral obstruction, anastomotic leak, or hypovolemia.

Pain management. Cystectomy is a major abdominal/pelvic surgery. Epidural analgesia or patient-controlled analgesia (PCA) are standard post-operative pain management modalities. Adequate pain control is essential for early ambulation, which is critical for DVT prophylaxis.

DVT prophylaxis. Bladder cancer patients undergoing radical cystectomy are at high risk for venous thromboembolism — major pelvic surgery, malignancy, and prolonged operative time each independently elevate risk. Nursing DVT prophylaxis measures include sequential compression devices (SCDs), early ambulation, and anticoagulation per protocol. See the DVT nursing reference for full prophylaxis and monitoring detail.

Bowel function. Because bowel is isolated for conduit or neobladder construction, a functional ileus is expected post-operatively. Patients receive bowel rest initially. Monitor for return of bowel sounds and passage of flatus before advancing diet.

Psychosocial care. Cystectomy and urinary diversion represent a profound body image change. Younger patients may face sexual dysfunction (erectile dysfunction in men from nerve injury; vaginal changes in women), altered continence, and the visible presence of a stoma. Nursing should proactively address body image concerns, involve the enterostomal therapy (ET) nurse specialist, and connect patients with ostomy support resources. Colorectal cancer nursing covers stoma care principles that apply across diversion types, including the comparison between colostomy and urostomy management.

Surveillance and recurrence

Bladder cancer surveillance protocols reflect the high recurrence rate of NMIBC — the disease is characteristically an ongoing condition rather than a cured cancer, even after complete surgical resection.

Standard surveillance schedule for NMIBC (low/intermediate risk):

• Cystoscopy every 3 months for the first 2 years
• Every 6 months for years 3–5
• Annually thereafter, indefinitely

High-risk NMIBC and MIBC require more intensive follow-up including CT urography to screen for upper tract recurrence (which occurs in 2–4% of patients) and to evaluate for local and distant relapse.

Signs of recurrence to include in patient discharge education: hematuria (painless or otherwise), return of irritative voiding symptoms, new back or flank pain (possible ureteral recurrence or obstruction), and constitutional symptoms.

Patients should understand that cystoscopy is not optional follow-up — it is the detection method for a disease with a 60–70% recurrence rate in the first two years. Attendance at surveillance appointments should be part of discharge counseling at every care encounter.

Nephrolithiasis and pyelonephritis remain diagnostic considerations in the surveillance setting — new hematuria or flank pain in a cystectomy patient should not be attributed to these benign causes without excluding recurrent cancer first. For patients with ileal diversions, the CKD nursing reference covers the chronic metabolic consequences of intestinal urinary diversion.

NCLEX review: high-yield tips

• Painless hematuria is the classic bladder cancer presentation — never attribute painless hematuria in an older adult to a benign cause without cystoscopic exclusion of malignancy.
• BCG is a live attenuated mycobacterium (M. bovis) — not a chemotherapy drug; it triggers an immune response in the bladder mucosa.
• After BCG instillation, the patient must retain the solution for 2 hours in the bladder before voiding.
• BCG post-void protocol: pour undiluted household bleach into the toilet and wait 15–20 minutes before flushing — repeat this for every void in the 6 hours following treatment.
• BCG sepsis is a life-threatening emergency: fever >38.5°C plus systemic signs (rigors, hemodynamic instability) after BCG = hold all further BCG doses, start anti-tuberculosis therapy, refer urgently.
• Contraindications to BCG: active UTI, gross hematuria, traumatic catheterization, immunocompromise — any one is sufficient to hold the dose.
• Mucus in the urostomy drainage bag is normal — the ileal conduit segment retains mucus-secreting goblet cells.
• Stoma color assessment is the priority stoma nursing assessment: beefy red and moist = healthy; dark, dusky, or black = ischemia → immediate surgical escalation.
• Ileal conduit patients develop hyperchloremic metabolic acidosis over time — the ileal mucosa exchanges Cl⁻ for HCO₃⁻ when in contact with urine.
• Neobladder patients do not sense filling and cannot void reflexively — they must void on a schedule using Valsalva or Credé, and learn intermittent catheterization for incomplete emptying.
• Cystoscopy with biopsy is the gold standard for bladder cancer diagnosis — CT and urine cytology are adjuncts, not replacements.
• TURBT is simultaneously diagnostic (provides tissue for staging) and therapeutic (removes visible tumor) — understand both roles.
• Muscle-invasive disease (T2+) = radical cystectomy (complete bladder removal) — partial resection is not the standard approach.
• Non-muscle-invasive bladder cancer has a 60–70% recurrence rate — surveillance cystoscopy every 3 months for the first 2 years is mandatory, not optional.
• Schistosomiasis (S. haematobium) → squamous cell carcinoma of the bladder (not urothelial/TCC) — remember the histologic link.
• Pembrolizumab and atezolizumab are immune checkpoint inhibitors approved for bladder cancer — monitor for irAEs across all organ systems (pneumonitis, colitis, hepatitis, endocrinopathy).
• Cyclophosphamide use is a risk factor for bladder cancer via acrolein metabolite — mesna is co-administered with high-dose cyclophosphamide to prevent urothelial damage.
• Ureteral stents visible at the stoma in the immediate post-operative period are normal and expected — they protect the ureteral anastomoses and are removed at the first clinic visit.

Summary

Bladder cancer nursing requires competence across a wide clinical arc: recognizing the cardinal presenting sign (painless hematuria), understanding the staging system that drives treatment, managing the specific safety protocols of live BCG intravesical therapy, and providing expert post-operative care after radical cystectomy and urinary diversion. The high recurrence rate of non-muscle-invasive disease means that long-term nurse-patient relationships around surveillance are intrinsic to bladder cancer care — not an afterthought. For broader oncology nursing context, the oncology nursing reference covers cancer care principles applicable across disease sites. The prostate cancer nursing reference addresses other GU oncology scenarios including post-prostatectomy care and androgen deprivation therapy management.